Clinical Trial Update: Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL [Phase 3]

View source ↗

Summary

Phase 3 trial comparing romidepsin alone to romidepsin plus pralatrexate in peripheral T-cell lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Pralatrexate (pralatrexate)
• Romidepsin (romidepsin)

Snippet

Sponsor: Jennifer Amengual | Conditions: Lymphoma, T-Cell, Peripheral | Phase 3 | Status: WITHDRAWN